OXvax Ltd. is a spin out company from the University of Oxford focused on the development of an advanced next generation dendritic cell vaccine platform for the treatment of solid tumour cancers.
The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology and exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary subset whose unique properties make them attractive candidates for cancer immunotherapy.
Company Details
- Founded
- -
- Address
- 264 Banbury Road, Oxford,england Ox2 7dy,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.oxvax.uk
- HQ
- Oxford, England
Oxvax Ltd Questions
Oxvax Ltd's website is http://www.oxvax.uk
Oxvax Ltd's LinkedIn profile is https://uk.linkedin.com/company/oxvax-ltd
Oxvax Ltd's industry is
Biotechnology Research
Oxvax Ltd's top competitors are
Immunocore,
Infinitopes,
Enara Bio,
Mursla Bio,
Orfonyx Bio,
Bioescalator,
Oxford Vacmedix Uk Limited,
Accession Therapeutics Limited,
Alethiomics,
Oxford Cancer Analytics.
Oxvax Ltd's categories are Biotechnology Research
Oxvax Ltd's founding year is 2021
